Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
19 02 2019
Historique:
received: 14 12 2018
revised: 08 02 2019
accepted: 14 02 2019
entrez: 23 2 2019
pubmed: 23 2 2019
medline: 23 2 2019
Statut: epublish

Résumé

Wound healing fluid that originates from breast surgery increases the aggressiveness of cancer cells that remain after the surgery. We determined the effects of the extent of surgery and tumor-driven remodeling of the surrounding microenvironment on the ability of wound-healing to promote breast cancer progression. In our analysis of a panel of 34 cytokines, chemokines, and growth factors in wound healing fluid, obtained from 27 breast carcinoma patients after surgery, the levels of several small molecules were associated with the extent of cellular damage that was induced by surgery. In addition, the composition of the resulting wound healing fluid was associated with molecular features of the removed tumor. Specifically, IP-10, IL-6, G-CSF, osteopontin, MIP-1a, MIP-1b, and MCP1-MCAF were higher in more aggressive tumors. Altogether, our findings indicate that the release of factors that are induced by removal of the primary tumor and subsequent wound healing is influenced by the extent of damage due to surgery and the reactive stroma that is derived from the continuously evolving network of interactions between neoplastic cells and the microenvironment, based on the molecular characteristics of breast carcinoma cells.

Identifiants

pubmed: 30791501
pii: cells8020181
doi: 10.3390/cells8020181
pmc: PMC6406730
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Breast Cancer. 2012 Apr;19(2):118-24
pubmed: 22139728
Lancet. 2003 Aug 16;362(9383):527-33
pubmed: 12932384
Nurs Res. 2008 Jan-Feb;57(1):51-8
pubmed: 18091292
J Cell Physiol. 2015 Nov;230(11):2661-70
pubmed: 25711523
Oncotarget. 2016 Oct 25;7(43):69649-69665
pubmed: 27626701
J Am Coll Clin Wound Spec. 2014 Mar 24;4(4):84-91
pubmed: 26199879
Mol Oncol. 2014 Jul;8(5):968-81
pubmed: 24747080
Oncol Lett. 2011 Jul;2(4):583-589
pubmed: 22848232
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
J Cell Commun Signal. 2009 Dec;3(3-4):311-22
pubmed: 19798593
Cancer Growth Metastasis. 2015 Jan 29;8:1-13
pubmed: 25674014
BMC Cancer. 2018 May 23;18(1):586
pubmed: 29792166
Cancer Res. 2014 Sep 1;74(17):4706-19
pubmed: 25035397
Anesth Analg. 2010 Jun 1;110(6):1630-5
pubmed: 20435950
Gut. 2013 Mar;62(3):461-70
pubmed: 22147551
Arch Surg. 1998 Apr;133(4):383-9
pubmed: 9565118
Curr Pharm Biotechnol. 2011 Nov;12(11):1900-8
pubmed: 21470134
J Immunother. 2010 Jan;33(1):8-15
pubmed: 19952960
Oncoimmunology. 2016 May 11;5(5):e1093722
pubmed: 27467926
Br J Cancer. 1997;75(7):1021-7
pubmed: 9083338
Indian J Plast Surg. 2012 May;45(2):220-8
pubmed: 23162220
Lancet. 1995 Dec 9;346(8989):1528-30
pubmed: 7491049
Eur J Clin Invest. 2008 Jun;38(6):438-46
pubmed: 18452545
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Cancers (Basel). 2014 Aug 29;6(3):1753-68
pubmed: 25256831
Cell Death Dis. 2018 Mar 2;9(3):356
pubmed: 29500465
J Transl Med. 2016 Jan 25;14:25
pubmed: 26810896
Oncotarget. 2015 Oct 6;6(30):29296-310
pubmed: 26313265
Immunity. 2011 Oct 28;35(4):467-77
pubmed: 22035839
J Natl Cancer Inst. 2018 Oct 1;110(10):1115-1122
pubmed: 29718396
World J Surg. 2004 Mar;28(3):242-6
pubmed: 14961196
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643230
Eur J Cancer. 2006 May;42(8):1057-61
pubmed: 16624551
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
EMBO J. 2015 Sep 2;34(17):2219-36
pubmed: 26136213
Curr Med Chem. 2013;20(33):4163-76
pubmed: 23992307
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Breast Cancer Res Treat. 1996;41(2):177-85
pubmed: 8944336
Am Surg. 2000 May;66(5):444-50; discussion 450-1
pubmed: 10824744
Crit Rev Oncol Hematol. 2014 Jan;89(1):16-26
pubmed: 23958676
Oncoimmunology. 2016 Sep 20;5(11):e1234571
pubmed: 27999750
Nat Clin Pract Oncol. 2007 Dec;4(12):699-710
pubmed: 18037874
Oncol Lett. 2013 Dec;6(6):1559-1564
pubmed: 24260046
Physiol Rev. 2003 Jul;83(3):835-70
pubmed: 12843410
Plast Surg Int. 2013;2013:146764
pubmed: 23984063
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302

Auteurs

Roberto Agresti (R)

Division of Surgical Oncology, Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. Roberto.agresti@istitutotumori.mi.it.

Tiziana Triulzi (T)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. Tiziana.triulzi@istitutotumori.mi.it.

Marianna Sasso (M)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. Marianna.sasso@gmail.com.

Cristina Ghirelli (C)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. ghirelli.cristina@istitutotumori.mi.it.

Piera Aiello (P)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. piera.chef@gmail.com.

Ilona Rybinska (I)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. ilona.rybinska@istitutotumori.mi.it.

Manuela Campiglio (M)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. manuela.campiglio@me.com.

Lucia Sfondrini (L)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, 20133 Milan, Italy. Lucia.sfondrini@unimi.it.

Elda Tagliabue (E)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. elda.tagliabue@istitutotumori.mi.it.

Francesca Bianchi (F)

Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. francesca.bianchi@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH